Clinical Trials
151 trialsA Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery
Montefiore Medical Center
TraveraRTGx
Travera Inc
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
AstraZeneca
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
AIDS Malignancy Consortium
FORTITUDE-301
Amgen
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
City of Hope Medical Center
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
CRISPR Therapeutics
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Laekna Limited
AYAConnect
UNC Lineberger Comprehensive Cancer Center
Enhancing Cancer Prevention and Control Pathways-Native Health Initiative
New Mexico Cancer Research Alliance
FIDURA
Sahlgrenska University Hospital
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Institutes of Health Clinical Center (CC)
ARC-12
Arcus Biosciences, Inc.
EARN
Washington University School of Medicine
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
KEYVIBE-005
Merck Sharp & Dohme LLC
CNSI-Fe(II)
Sichuan Enray Pharmaceutical Sciences Company
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
P-COC
University of Alabama at Birmingham
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Genomic Testing and Resulting Medical Decisions
Arbeitsgemeinschaft medikamentoese Tumortherapie
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Exelixis
PEVOsq
UNICANCER
PRISMS
UNC Lineberger Comprehensive Cancer Center
VolATIL
Centre Hospitalier Universitaire de Besancon
ROOT
Taproot Health
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Symphogen A/S
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
A Chatbot Intervention for Reducing HPV Vaccine Hesitancy
University of Maryland, College Park
Safety of Effivia®, a Bevacizumab Biosimilar
Laboratorios Liomont
AURA
UNC Lineberger Comprehensive Cancer Center
RADIANT
DxTerity Diagnostics
DUET-3
Xencor, Inc.
Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
Gene Surgery LLC
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Cancer Research and Biostatistics Clinical Trials Consortium
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
A Message Framing Intervention for Increasing Parental Acceptance of Human Papillomavirus Vaccination
University of Maryland, College Park
Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
Dana-Farber Cancer Institute
MIFADORESOL
Institut de cancérologie Strasbourg Europe
MORRIS
Umeå University
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
MacroGenics
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
Three Birds With One Stone
University of Aarhus
Ask Questions (ASQ):Implementation of a Communication Intervention
Barbara Ann Karmanos Cancer Institute
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
DUET-4
Xencor, Inc.